Ocata Therapeutics, Inc. OCAT is a clinical stage biotechnology company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on OCAT’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Ocata Therapeutics could be a solid choice for investors.
Current Quarter Estimates for OCAT
In the past 30 days, 1 estimate has gone higher for Ocata Therapeutics while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates narrowing from a loss of 20 cents a share 30 days ago, to a loss of 12 cents today, a move of 40%.
Current Year Estimates for OCAT
Meanwhile, Ocata Therapeutics’ current year figures are also looking quite promising, with 2 estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of 80 cents per share 30 days ago to a loss of 62 cents per share today, an increase of 22.5%.
Bottom Line
The stock has also started to move higher lately, adding 78.5% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #2 (Buy) stock to profit in the near future.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment